NeoGenomics, Inc. (NEO)

15,50 +0,37 (+2,45%) Al cierre: 04:00PM EDT

NeoGenomics, Inc.

9490 NeoGenomics Way
Fort Myers, FL 33912
United States
239 768 0600
https://www.neogenomics.com

Sector(es): Healthcare
Sector: Diagnostics & Research
Empleados a tiempo completo: 2100

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Christopher Michael Smith BSc	CEO & Director	2,86M	N/A	1963
Mr. Jeffrey S. Sherman M.B.A.	Chief Financial Officer	1,17M	N/A	1966
Mr. Vishal Sikri	President of Advanced Diagnostics	1,08M	N/A	1976
Ms. Melody Harris Esq., J.D.	President & COO of Informatics	1,4M	N/A	1967
Mr. Warren Stone	Chief Commercial Officer	1,42M	N/A	1973
Mr. Gregory D. Aunan	Chief Accounting Officer	N/A	N/A	1969
Ms. Kendra Sweeney	Vice President of Investor Relations & Communications	N/A	N/A	N/A
Ms. Alicia Olivo	Executive VP of Business Development, General Counsel & Corporate Secretary	N/A	N/A	1984
Mr. Hutan Hashemi J.D.	Chief Compliance Officer	N/A	N/A	1979
Dr. Derek Lyle M.D.	Chief Medical Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Gobierno corporativo

El ISS Governance QualityScore de NeoGenomics, Inc., a día 1 de mayo de 2024, es 7. Las puntuaciones base son Auditoría: 5; Tablero: 2; Derechos de los accionistas: 3; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.